<DOC>
	<DOCNO>NCT02801656</DOCNO>
	<brief_summary>Clostridium difficile associate diarrhea ( CDAD ) significant cause morbidity mortality , cause loss healthy gut flora . Conventional treatment use antibiotic kill Clostridium difficile . A novel treatment use replacement gut flora fecal microbiota transplant ( FMT ) . Randomized trial establish safety efficacy FMT recurrent CDAD , trial use FMT primary CDAD . This study randomize patient oral encapsulate FMT oral Vancomycin .</brief_summary>
	<brief_title>Fecal Microbiota Transplantation Primary Clostridium Difficile Diarrhea</brief_title>
	<detailed_description>Patients primary CDAD approach consent randomize equally two arm : oral FMT oral Vancomycin placebo , oral FMT placebo oral Vancomycin . FMT prepare anonymous donor screen accord Health Canada guideline store frozen .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>life expectancy &gt; 3 month , 3 unformed stool 24 hour prior randomization , positive stool test within 72 hour randomization pregnancy , previous stool test positive within 12 month , toxic megacolon ileus , already receive &gt; 4 dos treatment current episode , inflammatory bowel disease , gastrointestinal surgery within 90 day randomization ( except appendectomy cholecystectomy ) , document aspiration gastric content within 90 day randomization , requirement treatment oral probiotic , opiate , loperamide diphenoxylate study duration , anticipate use antibiotic reason study duration , know nonCDAD concurrent gastrointestinal infection , concurrent enrollment another clinical trial reason , intolerance hypersensitivity Vancomycin , anaphylactic reaction food , current induction chemotherapy , HIV infection Cluster Differentiation 4 ( CD4 ) count &lt; 200 , medical nonmedical condition consider investigator preclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>